CU24515B1 - PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PYRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATE OF SODIUM - Google Patents
PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PYRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATE OF SODIUMInfo
- Publication number
- CU24515B1 CU24515B1 CU2016000048A CU20160048A CU24515B1 CU 24515 B1 CU24515 B1 CU 24515B1 CU 2016000048 A CU2016000048 A CU 2016000048A CU 20160048 A CU20160048 A CU 20160048A CU 24515 B1 CU24515 B1 CU 24515B1
- Authority
- CU
- Cuba
- Prior art keywords
- sodium
- pyrimidin
- olate
- dosage forms
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se relaciona con formas sólidas de dosificación farmacéutica para administración oral que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio (ingrediente activo (I), de la fórmula:</p> <p>ESPACIO PARA FÓRMULA I</p> <p>caracterizadas porque el ingrediente activo (I) contiene del 10 al 40 % de la masa total de la formulación, y como excipientes: hidroxipropilmetilcelulosa (HPMC), celulosa microcristalina o manitol, croscarmelosa de sodio, estearil fumarato de sodio o glicerildiestearato.</p> <p>Estas formas sólidas son útiles como medicamentos en la profilaxis secundaria o el tratamiento de trastornos, particularmente trastornos cardiovasculares, fallo cardíaco, anemia, trastornos renales crónicos e insuficiencia renal. </p> <p> </p><p> The present invention relates to solid pharmaceutical dosage forms for oral administration comprising 1- [6- (morpholin-4-yl) pyrimidin-4-yl] -4- (1H-1,2,3-triazole -1-yl) -1H-pyrazol-5-olate sodium (active ingredient (I), of the formula: </p> <p> SPACE FOR FORMULA I </p> <p> characterized in that the active ingredient ( I) contains from 10 to 40% of the total mass of the formulation, and as excipients: hydroxypropylmethylcellulose (HPMC), microcrystalline cellulose or mannitol, croscarmellose sodium, sodium stearyl fumarate or glyceryl distearate. </p> <p> These forms Solid are useful as drugs in secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic kidney disorders, and kidney failure. </p> <p> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189145 | 2013-10-17 | ||
| PCT/EP2014/071855 WO2015055564A1 (en) | 2013-10-17 | 2014-10-13 | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160048A7 CU20160048A7 (en) | 2016-10-28 |
| CU24515B1 true CU24515B1 (en) | 2021-05-12 |
Family
ID=49356354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000048A CU24515B1 (en) | 2013-10-17 | 2014-10-13 | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PYRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATE OF SODIUM |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9827198B2 (en) |
| EP (1) | EP3057580B1 (en) |
| JP (1) | JP6525979B2 (en) |
| KR (1) | KR102330953B1 (en) |
| CN (1) | CN105636580B (en) |
| AP (1) | AP2016009135A0 (en) |
| AR (1) | AR098064A1 (en) |
| AU (1) | AU2014336389B2 (en) |
| BR (1) | BR112016007588A2 (en) |
| CA (1) | CA2927437C (en) |
| CL (1) | CL2016000857A1 (en) |
| CU (1) | CU24515B1 (en) |
| DK (1) | DK3057580T3 (en) |
| DO (1) | DOP2016000078A (en) |
| EA (1) | EA032932B1 (en) |
| ES (1) | ES2868228T3 (en) |
| GT (1) | GT201600072A (en) |
| HR (1) | HRP20210691T1 (en) |
| HU (1) | HUE054107T2 (en) |
| IL (1) | IL244933B (en) |
| JO (1) | JO3645B1 (en) |
| LT (1) | LT3057580T (en) |
| MA (1) | MA38974B2 (en) |
| MX (1) | MX2016004628A (en) |
| MY (1) | MY190202A (en) |
| NI (1) | NI201600054A (en) |
| PE (1) | PE20160669A1 (en) |
| PH (1) | PH12016500716B1 (en) |
| SA (1) | SA516370940B1 (en) |
| SI (1) | SI3057580T1 (en) |
| TN (1) | TN2016000135A1 (en) |
| TW (1) | TWI746418B (en) |
| UA (1) | UA119855C2 (en) |
| UY (1) | UY35784A (en) |
| WO (1) | WO2015055564A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108993C (en) * | 2018-08-31 | 2023-10-17 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006050516A1 (en) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure |
| EP2133096A4 (en) * | 2007-03-13 | 2011-11-16 | Dainippon Sumitomo Pharma Co | Oral disintegrating tablet |
| DE102010044131A1 (en) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituted sodium 1H-pyrazole-5-olate |
-
2014
- 2014-10-13 PE PE2016000498A patent/PE20160669A1/en unknown
- 2014-10-13 TN TN2016000135A patent/TN2016000135A1/en unknown
- 2014-10-13 MX MX2016004628A patent/MX2016004628A/en unknown
- 2014-10-13 ES ES14783642T patent/ES2868228T3/en active Active
- 2014-10-13 KR KR1020167009621A patent/KR102330953B1/en active IP Right Grant
- 2014-10-13 EA EA201690788A patent/EA032932B1/en not_active IP Right Cessation
- 2014-10-13 EP EP14783642.3A patent/EP3057580B1/en active Active
- 2014-10-13 DK DK14783642.3T patent/DK3057580T3/en active
- 2014-10-13 US US15/029,215 patent/US9827198B2/en active Active
- 2014-10-13 CA CA2927437A patent/CA2927437C/en active Active
- 2014-10-13 JP JP2016523207A patent/JP6525979B2/en active Active
- 2014-10-13 WO PCT/EP2014/071855 patent/WO2015055564A1/en active Application Filing
- 2014-10-13 MA MA38974A patent/MA38974B2/en unknown
- 2014-10-13 SI SI201431801T patent/SI3057580T1/en unknown
- 2014-10-13 AU AU2014336389A patent/AU2014336389B2/en not_active Ceased
- 2014-10-13 CU CU2016000048A patent/CU24515B1/en unknown
- 2014-10-13 BR BR112016007588A patent/BR112016007588A2/en not_active Application Discontinuation
- 2014-10-13 UA UAA201605150A patent/UA119855C2/en unknown
- 2014-10-13 MY MYPI2016701355A patent/MY190202A/en unknown
- 2014-10-13 CN CN201480056547.1A patent/CN105636580B/en active Active
- 2014-10-13 HU HUE14783642A patent/HUE054107T2/en unknown
- 2014-10-13 LT LTEP14783642.3T patent/LT3057580T/en unknown
- 2014-10-13 AP AP2016009135A patent/AP2016009135A0/en unknown
- 2014-10-15 UY UY0001035784A patent/UY35784A/en not_active Application Discontinuation
- 2014-10-15 TW TW103135607A patent/TWI746418B/en not_active IP Right Cessation
- 2014-10-16 JO JOP/2014/0295A patent/JO3645B1/en active
- 2014-10-17 AR ARP140103868A patent/AR098064A1/en unknown
-
2016
- 2016-04-04 IL IL244933A patent/IL244933B/en active IP Right Grant
- 2016-04-08 DO DO2016000078A patent/DOP2016000078A/en unknown
- 2016-04-12 CL CL2016000857A patent/CL2016000857A1/en unknown
- 2016-04-14 SA SA516370940A patent/SA516370940B1/en unknown
- 2016-04-14 NI NI201600054A patent/NI201600054A/en unknown
- 2016-04-14 GT GT201600072A patent/GT201600072A/en unknown
- 2016-04-15 PH PH12016500716A patent/PH12016500716B1/en unknown
-
2021
- 2021-05-04 HR HRP20210691TT patent/HRP20210691T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (en) | PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| BR112013032122A2 (en) | modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids | |
| EA201990424A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| PH12020550341A1 (en) | Niraparib formulations | |
| EA201990428A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| BR112018012870A2 (en) | methods and compositions for the treatment of crisis-related disorders | |
| CR20110704A (en) | COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| MX2017005163A (en) | Onapristone extended-release compositions and methods. | |
| CU24515B1 (en) | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PYRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATE OF SODIUM | |
| MX362485B (en) | Novel rock inhibitors. | |
| MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. | |
| EA201170583A1 (en) | NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA | |
| BR112016015175A2 (en) | PHARMACEUTICAL FORMULATION, METHOD FOR MANUFACTURING A PHARMACEUTICAL FORMULATION COMPRISING SILDENAFIL AND CLOMIPRAMINE AND TABLET | |
| EA201892837A1 (en) | PHYSIOLOGICALLY BALANCED COMPOUNDS FOR INJECTIONS, INCLUDING PHOSNET SUPPORTANT | |
| CR20160177A (en) | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) 1H-PIRAZOL-5-OLATO SODIUM | |
| MX2017012999A (en) | Pyrrolidone carboxylic acid (pca) for ophthalmic use. | |
| EA201500366A1 (en) | APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR | |
| RU2013127881A (en) | APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment | |
| EA201992816A1 (en) | PHARMACEUTICAL COMPOSITION AND MEDICINAL FORM THAT INCLUDES (E) -4- (2- (AMINOMETHYL) -3-FLOROLLYLOXY) -N-THR-BUTYLBENZAMIDE, METHOD FOR THEIR PREPARATION AND APPLICATION, APPLICATION | |
| RU2013157796A (en) | PHARMACEUTICAL COMPOSITION BASED ON MOXIFLOXACIN | |
| UA97982U (en) | DRESSING MEDICINE FOR TABLETS | |
| RU2011128758A (en) | PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION |